Cellosaurus logo
expasy logo

Cellosaurus MDA-MB-435 (CVCL_0417)

[Text version]
Cell line name MDA-MB-435
Synonyms MDA-MB435; MDAMB435; MDA.MB.435; MDA-435; MDA 435; MDA435; MD Anderson-Metastatic Breast-435
Accession CVCL_0417
Resource Identification Initiative To cite this cell line use: MDA-MB-435 (RRID:CVCL_0417)
Comments Problematic cell line: Contaminated. Shown to be a M14 derivative (PubMed=17004106; PubMed=18304946; PubMed=20143388; PubMed=28940260). Originally thought to originate from the pleural effusion of a breast carcinoma from a 31 year old patient. See also PubMed=19549886 for a dissenting but incorrect view that states that M14 is a breast cancer cell line.
Part of: GrayJW breast cancer cell line panel.
Part of: NCI-60 cancer cell line panel.
Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00235.
Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12583.
Population: Caucasian.
Doubling time: 25.8 hours (NCI-DTP=MDA-MB-435); 38.72 hours (GrayJW panel).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: DNA methylation analysis.
Omics: Fluorescence phenotype profiling.
Omics: lncRNA expression profiling.
Omics: Metabolome analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Omics: Transcriptome analysis by serial analysis of gene expression (SAGE).
Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000351). It was one of the sources for the STR profile of this entry.
Misspelling: MDA-MB-43; Note=Occasionally.
Derived from site: Metastatic; Right buttock, hypodermis; UBERON=UBERON_0013691+UBERON_0002072.
Sequence variations
  • Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=17088437; PubMed=28889351).
  • Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=17088437).
  • Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (PubMed=17088437).
  • Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (PubMed=17088437; PubMed=28889351).
HLA typing Source: PubMed=15748285
Class I
HLA-AA*11:01:01,24:02:01
HLA-BB*15,35
HLA-CC*03:03:01,04
Class II
HLA-DPDPB1*13:01,19:01
HLA-DQDQB1*03:02,06:03
HLA-DRDRB1*04:05:01,13:01:01

Source: PubMed=26589293
Class I
HLA-AA*24:02,24:02
HLA-BB*15:01,15:01
HLA-CC*03:03,03:03
Class II
HLA-DQDQA1*01:03,01:03
DQB1*06:03,06:03
HLA-DRDRB1*03:17,13:01
Disease Amelanotic melanoma (NCIt: C3802)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_1395 (M14)
Children:
CVCL_0124 (435.eB)CVCL_B057 (M4A4)CVCL_J435 (MDA 435TR)
CVCL_R957 (MDA-MB-435-BAG)CVCL_B055 (MDA-MB-435-LCC15)CVCL_4Y10 (MDA-MB-435-Luc#1)
CVCL_0622 (MDA-MB-435S)CVCL_1910 (MDA-N)CVCL_IN99 (MDA435/LCC6)
CVCL_B064 (NM2C5)
Sex of cell Male
Age at sampling 33Y
Category Cancer cell line
STR profile Source(s): CCRID; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=25877200; PubMed=28889351

Markers:
AmelogeninX
CSF1PO11
D2S133819,24
D3S135814
D5S81811,12 (CCRID; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=28889351)
12 (PubMed=25877200)
D7S8208,10
D8S117913
D13S31712
D16S53913
D18S5113 (PubMed=25877200)
13,17 (CCRID; DOI=10.4172/2157-7145.S2-005; PubMed=19372543)
D19S43314 (CCRID; DOI=10.4172/2157-7145.S2-005; PubMed=25877200)
14,15 (PubMed=19372543)
D21S1129,31.2 (PubMed=28889351)
30 (CCRID; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=25877200)
FGA21
Penta D9,11
Penta E10,12
TH016,7
TPOX8,11
vWA16,18

Run an STR similarity search on this cell line
Web pages https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
https://dtp.cancer.gov/discovery_development/nci-60/mda-mb-435.htm
https://strap.nci.nih.gov/celline_detail.php?sample_id=51
https://www.cellosaurus.org/pawefish/BreastCellLineDescriptions/mda-mb-435.htm
https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
https://www.ncbi.nlm.nih.gov/pubmed/25902968#cm25902968_13561
https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
Publications

PubMed=730202; DOI=10.1007/BF02616120
Cailleau R.M., Olive M., Cruciger Q.V.J.
Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization.
In Vitro 14:911-915(1978)

PubMed=7272986; DOI=10.1016/0165-4608(81)90057-1
Satya-Prakash K.L., Pathak S., Hsu T.-C., Olive M., Cailleau R.M.
Cytogenetic analysis on eight human breast tumor cell lines: high frequencies of 1q, 11q and HeLa-like marker chromosomes.
Cancer Genet. Cytogenet. 3:61-73(1981)

PubMed=10700174; DOI=10.1038/73432
Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.
Systematic variation in gene expression patterns in human cancer cell lines.
Nat. Genet. 24:227-235(2000)

PubMed=10969801
Forozan F., Mahlamaki E.H., Monni O., Chen Y.-D., Veldman R., Jiang Y., Gooden G.C., Ethier S.P., Kallioniemi A., Kallioniemi O.-P.
Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.
Cancer Res. 60:4519-4525(2000)

PubMed=11044355; DOI=10.1054/bjoc.2000.1458
Davidson J.M., Gorringe K.L., Chin S.-F., Orsetti B., Besret C., Courtay-Cahen C., Roberts I., Theillet C., Caldas C., Edwards P.A.W.
Molecular cytogenetic analysis of breast cancer cell lines.
Br. J. Cancer 83:1309-1317(2000)

PubMed=15153330; DOI=10.1593/neo.3292
Watts G.S., Oshiro M.M., Junk D.J., Wozniak R.J., Watterson S.J., Domann F.E., Futscher B.W.
The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells.
Neoplasia 6:187-194(2004)

PubMed=15748285; DOI=10.1186/1479-5876-3-11
Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. III, Stroncek D., Marincola F.M.
HLA class I and II genotype of the NCI-60 cell lines.
J. Transl. Med. 3:11.1-11.8(2005)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433
Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008
Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Cancer Cell 10:515-527(2006)

PubMed=17004106; DOI=10.1007/s10549-006-9392-8
Rae J.M., Creighton C.J., Meck J.M., Haddad B.R., Johnson M.D.
MDA-MB-435 cells are derived from M14 melanoma cells -- a loss for breast cancer, but a boon for melanoma research.
Breast Cancer Res. Treat. 104:13-19(2007)

PubMed=18304946; DOI=10.1093/nar/gkn089
Demichelis F., Greulich H., Macoska J.A., Beroukhim R., Sellers W.R., Garraway L.A., Rubin M.A.
SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines.
Nucleic Acids Res. 36:2446-2456(2008)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921
Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.
DNA fingerprinting of the NCI-60 cell line panel.
Mol. Cancer Ther. 8:713-724(2009)

PubMed=19549886; DOI=10.1158/0008-5472.CAN-09-1528
Chambers A.F.
MDA-MB-435 and M14 cell lines: identical but not M14 melanoma?
Cancer Res. 69:5292-5293(2009)

CLPUB00423
Morrison B.J.
Breast cancer stem cells: tumourspheres and implications for therapy.
Thesis PhD (2010), Griffith University, Australia

PubMed=20143388; DOI=10.1002/ijc.25242
Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A., MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R., Freshney R.I.
Check your cultures! A list of cross-contaminated or misidentified cell lines.
Int. J. Cancer 127:1-8(2010)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

DOI=10.4172/2157-7145.S2-005
Fang R.-X., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M., Hart R.P., Furtado M.R.
STR profiling of human cell lines: challenges and possible solutions to the growing problem.
J. Forensic Res. 2 Suppl. 2:5-5(2011)

PubMed=22068913; DOI=10.1073/pnas.1111840108
Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)

PubMed=22347499; DOI=10.1371/journal.pone.0031628
Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.
Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.
PLoS ONE 7:E31628-E31628(2012)

PubMed=22384151; DOI=10.1371/journal.pone.0032096
Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
PLoS ONE 7:E32096-E32096(2012)

PubMed=22628656; DOI=10.1126/science.1218595
Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Science 336:1040-1044(2012)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342
Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Cancer Res. 73:4372-4382(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018
Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C., Wilhelm M., Kuster B.
Global proteome analysis of the NCI-60 cell line panel.
Cell Rep. 4:609-620(2013)

PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020
Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A., Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K., McCormick F., Gray J.W.
Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.
Cancer Cell 24:450-465(2013)

PubMed=24162158; DOI=10.1007/s10549-013-2743-3
Prat A., Karginova O., Parker J.S., Fan C., He X.-P., Bixby L.M., Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M.
Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.
Breast Cancer Res. Treat. 142:237-255(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20
Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Cancer Metab. 1:20.1-20.13(2013)

PubMed=24670534; DOI=10.1371/journal.pone.0092047
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
PLoS ONE 9:E92047-E92047(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=28721362; DOI=10.1038/npjbcancer.2015.2
Prasad V.V.T.S., Gopalan R.O.G.
Continued use of MDA-MB-435, a melanoma cell line, as a model for human breast cancer, even in year, 2014.
NPJ Breast Cancer 1:15002.1-15002.2(2015)

PubMed=27377824; DOI=10.1038/sdata.2016.52
Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4
Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Mob. DNA 7:20.1-20.11(2016)

PubMed=28940260; DOI=10.1002/ijc.31067
Korch C.T., Hall E.M., Dirks W.G., Ewing M., Faries M., Varella-Garcia M., Robinson S., Storts D.R., Turner J.A., Wang Y., Burnett E.C., Healy L.E., Kniss D.A., Neve R.M., Nims R.W., Reid Y.A., Robinson W.A., Capes-Davis A.
Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line.
Int. J. Cancer 142:561-572(2017)

PubMed=28889351; DOI=10.1007/s10549-017-4496-x
Saunus J.M., Smart C.E., Kutasovic J.R., Johnston R.L., Kalita-de Croft P., Miranda M., Rozali E.N., Vargas A.C., Reid L.E., Lorsy E., Cocciardi S., Seidens T., McCart Reed A.E., Dalley A.J., Wockner L.F., Johnson J., Sarkar D., Askarian-Amiri M.E., Simpson P.T., Khanna K.K., Chenevix-Trench G., Al-Ejeh F., Lakhani S.R.
Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.
Breast Cancer Res. Treat. 167:289-301(2018)

Cross-references
Cell line collections (Providers) NCI-DTP; MDA-MB-435
Cell line databases/resources MCCL; MCC:0000314
cancercelllines; CVCL_0417
Cell_Model_Passport; SIDM00004
SKY/M-FISH/CGH; 2816
TOKU-E; 3544
Anatomy/cell type resources BTO; BTO:0001567
Biological sample resources BioSample; SAMN03151832
BioSample; SAMN03470861
Chemistry resources ChEMBL-Cells; CHEMBL3307686
ChEMBL-Targets; CHEMBL614697
PharmacoDB; MDAMB435_904_2019
PubChem_Cell_line; CVCL_0417
Encyclopedic resources Wikidata; Q50952937
Experimental variables resources EFO; EFO_0001213
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2706
ArrayExpress; E-TABM-157
GEO; GSM2095
GEO; GSM50203
GEO; GSM50265
GEO; GSM206523
GEO; GSM274648
GEO; GSM274649
GEO; GSM344352
GEO; GSM344402
GEO; GSM383801
GEO; GSM383802
GEO; GSM383803
GEO; GSM743466
GEO; GSM750814
GEO; GSM783965
GEO; GSM799354
GEO; GSM799417
GEO; GSM844589
GEO; GSM844590
GEO; GSM847037
GEO; GSM1008908
GEO; GSM1153424
GEO; GSM1178391
GEO; GSM1178392
GEO; GSM1181294
GEO; GSM1181337
GEO; GSM1215267
GEO; GSM1670084
GEO; GSM2124670
Polymorphism and mutation databases Cosmic; 687496
Cosmic; 875879
Cosmic; 905988
Cosmic; 974069
Cosmic; 974236
Cosmic; 991325
Cosmic; 1000131
Cosmic; 1010930
Cosmic; 1044219
Cosmic; 1092614
Cosmic; 1175834
Cosmic; 1176643
Cosmic; 1219445
Cosmic; 1305366
Cosmic; 1312349
Cosmic; 1477425
Cosmic; 1524346
Cosmic; 1571794
Cosmic; 1945861
Cosmic; 1998456
IARC_TP53; 18065
Progenetix; CVCL_0417
Proteomic databases PRIDE; PXD005942
PRIDE; PXD005946
Sequence databases EGA; EGAS00001000610
EGA; EGAS00001002554
Entry history
Entry creation04-Apr-2012
Last entry update05-Oct-2023
Version number40